First time available for research use


Atezolizumab antibody from Tecentriq®

Therapeutic PD-L1-antibody from the original Tecentriq® commercial drug targeting the PD-L1-antigen, also referred to as Tecentriq® or atezolizumab antibody. Research-relevant quantities are available as licence-free consumable in an aliquoted variant. Therapeutic monoclonal antibodies can be used from researchers in in vitro and in vivo experiments, biosimilar developers can order different batches at the same time.

Choose your antibody
Easy Access

Easy Access

Easy to order as license-free research consumable
Multiple batches

Multiple batches

Up to 10 batches of original drugs for examining batch-to-batch variations
Reduce costs

Reduce costs

Up to 80% less compared to the original pharmaceutical price
Prompt delivery

Prompt delivery

Shipment within days worldwide according to GDP-standards
Documented origin

Documented origin

Information on batch, registration number, expiry date, GDP-compliant pedigree

What our clients say

Atezolizumab / Tecentriq

Product Reference

Drug nameTecentriq®
API typeAtezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1)
monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionTecentriq works by attaching to a specific protein in your body called programmed death-ligand 1
(PD-L1). This protein suppresses the body’s immune (defense) system, thereby protecting cancer cells
from being attacked by the immune cells. By attaching to the protein, Tecentriq helps your immune
system to fight your cancer.
(Source EMA , package leaflet)
Short descriptionTecentriq is an anti-cancer medicine that contains the active substance atezolizumab.

Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating
immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour
microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen-presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that
directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour
immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers
Marketing authorisation holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
(Date of first authorisation: 21 September 2017)
Name of the manufacturer of the biological active substance
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Whylen
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
Glacial acetic acid
Polysorbate 20
Water for injections